Results 151 to 160 of about 63,205 (262)

Current Advances of Molecular Biomarkers and Liquid Biopsies Techniques in Ovarian Cancer

open access: yesCancer Medicine, Volume 15, Issue 8, August 2026.
ABSTRACT Ovarian cancer (OC) remains a lethal gynecological malignancy with challenges in early diagnosis, treatment monitoring, and overcoming drug resistance. Liquid biopsy, a noninvasive approach analyzing tumor‐derived components in bodily fluids, has emerged as a promising tool in OC management.
Jingxia Zhang   +5 more
wiley   +1 more source

Identification and Characterization of Novel Inhibitors of Human Poly(ADP-Ribose) Polymerase-1. [PDF]

open access: yesMolecules
Morgan I   +6 more
europepmc   +1 more source

Survival Impact of Programmed Cell Death Ligand‐1 Expression in Patients With Epithelial Ovarian Carcinoma

open access: yesCancer Reports, Volume 9, Issue 8, August 2026.
ABSTRACT Aims To evaluate the proportion of expressed programmed cell death ligands‐1 (PD‐L1) in epithelial ovarian carcinoma patients, and the association with the clinicopathological, surgical outcomes, and oncologic outcomes. To compare PD‐L1 protein expression with messenger ribonucleic acid (mRNA) expression. Methods The patients who had pathology
Achjima Tankul   +8 more
wiley   +1 more source

Real-world data-based assessment of therapy-related myeloid neoplasms after poly(ADP-ribose) polymerase inhibitor treatment in ovarian cancer. [PDF]

open access: yesFront Oncol
Uekusa R   +9 more
europepmc   +1 more source

SMAD4 Expression and Its Association With Treatment Resistance and Clinical Outcomes in Oral Squamous Cell Carcinoma Treated With Preoperative Chemoradiotherapy

open access: yesCancer Reports, Volume 9, Issue 8, August 2026.
ABSTRACT Background Small mothers against decapentaplegic homologue 4 (SMAD4) plays an important role in transforming growth factor (TGF)‐β signaling and is associated with various cancers. However, little is known about SMAD4 expression in oral squamous cell carcinoma (OSCC).
Junki Sakata   +15 more
wiley   +1 more source

Poly(ADP-ribose) polymerase (PARP) inhibitors and ovarian cancer

open access: yesTaiwanese Journal of Obstetrics & Gynecology, 2017
Chia-Hao Liu, Yi Chang
doaj   +1 more source

Genomic, Trop‐2, and Immune Profiles of Carcinomatous and Sarcomatous Components in Ovarian Carcinosarcoma

open access: yesCancer Reports, Volume 9, Issue 8, August 2026.
ABSTRACT Background Ovarian carcinosarcoma (OCS) is a rare, aggressive tumor composed of both carcinomatous and sarcomatous components, typically associated with poor prognosis. Due to its rarity, the molecular characteristics, immune microenvironment, and optimal treatment of OCS remain unclear.
Tomomi Sakamaki   +14 more
wiley   +1 more source

Home - About - Disclaimer - Privacy